<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01511874</url>
  </required_header>
  <id_info>
    <org_study_id>fr-HE530-01</org_study_id>
    <nct_id>NCT01511874</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer</brief_title>
  <official_title>Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HanAll BioPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HanAll BioPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of ELIGARD 22.5mg in the
      treatment of subjects with prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dl at 4 weeks after injection of ELIGARD 22.5mg</measure>
    <time_frame>4weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects whose blood testosterone concentration is maintained below 50ng/dL until 24weeks</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects whose blood testosterone concentration exceed 50ng/dL until 24weeks</measure>
    <time_frame>24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in self assessment scale grade</measure>
    <time_frame>0,4, 8, 12, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of subjects whose blood testosterone concentration is below 20ng/dL at 4weeks and 24weeks</measure>
    <time_frame>4, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECOG performance status</measure>
    <time_frame>0,4,8,12, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood prostate-specific antigen</measure>
    <time_frame>0,4,8,12,24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QoL_EPIC grade</measure>
    <time_frame>0,12, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in penile length</measure>
    <time_frame>screening, 12, 24weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in testicular volume</measure>
    <time_frame>screening, 12, 24weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ELIGRAD 22.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELIGARD 22.5mg</intervention_name>
    <description>a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks</description>
    <arm_group_label>ELIGRAD 22.5mg</arm_group_label>
    <other_name>ELIGARD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male of 20 years or above

          -  Subject with prostate cancer with TNM stage T2~4NxMx

          -  Blood testosterone concentration ≥ 100ng/dl

          -  Bilirubin ≤ 1.5xULN, transaminase ≤ 2.5xULN

          -  WHO ECOG performance status ≤ 2

          -  Signed written informed consent

        Exclusion Criteria:

          -  Hormone-Refractory Prostate cancer

          -  Brain metastasis

          -  Another primary malignant tumor except for prostate cancer

          -  Other conditions which in the opinion of the investigator preclude enrollment into the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Byung Ha Chung, Medicine</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Urology,Yonsei University,College of Medicine, Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2012</study_first_posted>
  <last_update_submitted>September 21, 2015</last_update_submitted>
  <last_update_submitted_qc>September 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ELIGARD</keyword>
  <keyword>Prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

